Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
AM García-Sancho, A Cabero… - Journal of Clinical …, 2023 - mdpi.com
Overall, around 40% of patients with diffuse large B-cell lymphoma (DLBCL) have refractory
disease or relapse after the first line of treatment. Until relatively recently, the prognosis of …
disease or relapse after the first line of treatment. Until relatively recently, the prognosis of …
The future of immunotherapy for diffuse large B‐cell lymphoma
J Duell, J Westin - International Journal of Cancer, 2024 - Wiley Online Library
With the introduction of anti‐CD19 chimeric antigen receptor (CAR) T‐cell (CAR T)
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …
Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma
J Lownik, J Boiarsky, R Birhiray, A Merchant… - Clinical Cancer …, 2024 - AACR
Several second-and third-line immunotherapeutic options for patients with relapsed or
refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant are …
refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant are …
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
F D'Alò, S Bellesi, E Maiolo, E Alma, F Bellisario… - Cancers, 2024 - mdpi.com
Simple Summary Diffuse large B cell lymphoma is the most common type of B cell
neoplasm, and can be cured by traditional chemoimmunotherapy in 60–70% of cases …
neoplasm, and can be cured by traditional chemoimmunotherapy in 60–70% of cases …
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
MC Pirosa, A Stathis, E Zucca - 2024 - Taylor & Francis
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require
additional treatments, especially those not eligible or not responding to high dose cytotoxic …
additional treatments, especially those not eligible or not responding to high dose cytotoxic …
Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory …
MS Kurte, AC Siefen, F Jakobs, T Poos… - European Journal of …, 2024 - Wiley Online Library
Objectives Novel interventions (axicabtagene ciloleucel [axi‐cel], lisocabtagene maraleucel
[liso‐cel], tafasitamab‐lenalidomide [Tafa‐L], polatuzumab‐rituximab‐bendamustine [pola …
[liso‐cel], tafasitamab‐lenalidomide [Tafa‐L], polatuzumab‐rituximab‐bendamustine [pola …
A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system
Z Xu, S Feng, D Huang, H Wang, J Liu… - Expert Opinion on Drug …, 2024 - Taylor & Francis
Background Tafasitamab is the first anti-CD19 monoclonal antibody approved for
relapsed/refractory diffuse large B-cell lymphoma patients ineligible for autologous stem cell …
relapsed/refractory diffuse large B-cell lymphoma patients ineligible for autologous stem cell …
[HTML][HTML] Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma
The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in
the field of lymphoma, as compared to traditional experimental clinical trials, are poised to …
the field of lymphoma, as compared to traditional experimental clinical trials, are poised to …
The current landscape of frontline large B cell lymphoma trials
Abstract At least 25-35% of patients with large B cell lymphoma (LBCL) are not cured with
frontline treatment, with generally poor subsequent outcomes. This motivates ongoing and …
frontline treatment, with generally poor subsequent outcomes. This motivates ongoing and …